When I was at Celera Genomics, working under Venter was like being in the middle of a scientific war zone. The man had this insatiable appetite for pushing the boundaries, pushing people to the edge, sometimes too far. We were racing against the publicly funded Human Genome Project, a David vs. Goliath situation but with data and DNA. Venter used his own DNA as a sequencing template, a bold move that took personalization to an entirely new level but also incited controversy over vanity or genius. What always intrigued me was the blend of innovation and ego that characterized his work. Sure, we were sequencing the human genome faster than anyone thought possible, but at what cost? The ethical implications were often sidelined by the allure of headlines and breaking scientific ground. Was it really about advancing human health, or was it more about proving a point, showing the world just how much faster private industry could move compared to a government-funded consortium? On that note, let's talk about competition and collaboration in science. In our industry, these lines often blur, with projects being driven by grants, patents, and rivalries more than by the quest for human advancement. I saw this exact dynamic playing out during the genome race, where the irony was that our process could have benefited from sharing and collaboration with the very people we competed against. As we look back at Venter's legacy, it's worth reflecting on how this race impacted the field. Did we redefine what it means to 'own' our genetic data? Is personalized medicine a step forward or just another way to commodify the most intrinsic parts of ourselves? The legacy of Venter is complex, a mixture of spectacular achievement and relentless ambition. Did the race for the first genome overshadow the science, or was it simply another chapter in the ongoing narrative of scientific discovery?